Old North State Wealth Management LLC Buys 659 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Old North State Wealth Management LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 58,548 shares of the biopharmaceutical company’s stock after purchasing an additional 659 shares during the quarter. Gilead Sciences comprises approximately 3.0% of Old North State Wealth Management LLC’s investment portfolio, making the stock its 8th largest position. Old North State Wealth Management LLC’s holdings in Gilead Sciences were worth $5,414,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of GILD. State Street Corp boosted its stake in Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after acquiring an additional 841,776 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares in the last quarter. FMR LLC grew its stake in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after buying an additional 14,680,161 shares during the period. Geode Capital Management LLC increased its position in Gilead Sciences by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after buying an additional 574,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Gilead Sciences by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company’s stock worth $650,009,000 after buying an additional 224,960 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 572,824 shares of company stock worth $53,611,715. 0.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent research reports. Oppenheimer boosted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Finally, Wolfe Research assumed coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Stock Down 0.4 %

GILD opened at $97.99 on Wednesday. The firm has a market capitalization of $122.12 billion, a P/E ratio of 1,088.78, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $99.45. The company has a fifty day moving average price of $92.58 and a 200-day moving average price of $86.14. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the prior year, the company earned $2.29 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. Equities research analysts expect that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.